AuditLine › HHS OIG › Centers for Medicare and Medicaid Services
HHS OIG recommendation 13-E-12-070.01
CMS should examine the additional potential impacts of establishing a prescription drug rebate program under Medicare Part B and, if appropriate,…
The recommendation, in the publisher's words
CMS should examine the additional potential impacts of establishing a prescription drug rebate program under Medicare Part B and, if appropriate, seek legislative change.
- Responsible agency
- Centers for Medicare and Medicaid Services
- Issued
- September 9, 2013
- Report
- Medicare Could Collect Billions If Pharmaceutical Manufacturers Were Required To Pay Rebates for Part B Drugs (OEI-12-12-00260) · find it at HHS OIG
- Kind of report
- Evaluation
- Agency response
- Concur (as recorded by the publisher)
- Closed
- April 13, 2023 (publisher's date)
- Publisher flags
- Legislative
- Publisher topics
- Financial Stewardship, Prescription Drug
“Open” and “closed” are the publisher's words. AuditLine repeats them with the date it read them. It does not check whether a recommendation was carried out, and a closed recommendation is not proof that a problem was fixed.
Dated history
- Issued by HHS OIG. (publisher's date)
- Closed, with status “Closed Implemented”. (publisher's date)
- First recorded by AuditLine. (start of AuditLine's own history for this record)
Dates marked "publisher's date" come from the publisher's file. AuditLine's own observations begin November 10, 2026 and are added each time the publisher's file changes.
Source
Open this report in HHS OIG's tracker This publisher's records (CSV)
Official export: https://oig.hhs.gov/recommendations/export-recs/. File read , 4,677 rows,
SHA-256 664fdfb3658ecb72…. HHS OIG's status, response, dates and potential-savings labels are the publisher's own claims.